19Evidence A

Don’t start taking uric‑acid‑lowering drugs just because a checkup shows high uric acid but you’ve never had symptoms

For people whose uric acid is over the limit but who have never had a gout attack or tophi, the American College of Rheumatology conditionally recommends not starting uric-acid–lowering drugs yet. Treat 24 people for 3 full years and you prevent only one gout attack. Hoping it protects the kidneys also fails: kidney patients on the drug still lose kidney function as fast as those on placebo. Treat only after a real attack.

Cost

There’s no cost at all;

Benefit

The 2020 gout guidelines from the American College of Rheumatology address asymptomatic hyperuricemia, defined…

Cost

There’s no cost at all; you also avoid long‑term medication expenses, regular follow‑ups, and the risks linked to unnecessary drug use.

Benefit

The 2020 gout guidelines from the American College of Rheumatology address asymptomatic hyperuricemia, defined as blood uric‑acid levels above 6.8 mg/dL in people who’ve never had gout or tophus. Under certain conditions the guidelines advise against initiating any uric‑acid‑lowering therapy — drugs such as allopurinol, febuxostat, or probenecid. Evidence supporting this recommendation is rated “high.” A footnote clarifies that, based on attributable risk, 24 patients must be treated for three years to prevent one gout episode. The CKD‑FIX trial enrolled 363 participants with stage 3 or 4 chronic kidney disease; they had no gout history but faced a higher risk of worsening kidney function. One group received 100–300 mg of allopurinol daily while the other got a placebo; after 104 weeks the annual change in eGFR — a key kidney‑function marker measured in mL/min/1.73 m² — was –3.33 (95 % CI –4.11 to –2.55) in the drug group versus –3.23 (–3.98 to –2.47) in the placebo group. The difference between groups was –0.10 (–1.18 to 0.97), with a P‑value of 0.85, meaning kidney‑function decline proceeded at the same pace. Serious adverse events occurred in 46 % of patients on allopurinol versus 44 % on placebo. The PERL trial involved 530 type 1 diabetics with early‑to‑moderate diabetic kidney disease; after three years of allopurinol therapy the drug was withdrawn for two months to gauge its effect. Allopurinol lowered blood uric‑acid from 6.1 mg/dL to 3.9 mg/dL, yet after discontinuation the eGFR difference between groups narrowed to just 0.001 mL/min/1.73 m² (95 % CI –1.9 to 1.9, P = 0.99). Moreover, urinary albumin excretion rose 40 % (range 0–80 %) in the allopurinol group. The apparent “benefit” stems largely from the intuitive notion that any elevated marker warrants medication.

Original sources

FitzGerald JD, Dalbeth N, Mikuls T, et al. (2020). 2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Care & Research, 72(6), 744-760(表 1 及其脚注). https://doi.org/10.1002/acr.24180;Badve SV, Pascoe EM, Tiku A, et al. (2020). Effects of Allopurinol on the Progression of Chronic Kidney Disease. New England Journal of Medicine, 382(26), 2504-2513. https://doi.org/10.1056/NEJMoa1915833;Doria A, Galecki AT, Spino C, et al. (2020). Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 382(26), 2493-2503. https://doi.org/10.1056/NEJMoa1916624

Open source link
Book note

What to reject is “start lifelong uric-acid–lowering drugs when you have never had an attack,” not “high uric acid does not matter.” The same guideline lists exceptions. The cases below may warrant starting. First: a first attack plus stage 3 or higher chronic kidney disease. Second: blood uric acid >9 mg/dL (about 535 µmol/L). Third: a history of urinary stones. People with tophi, bone erosion on imaging, or 2 or more attacks a year get a strong recommendation to take drugs; those with more than one attack but under 2 a year get a conditional recommendation. Details: Section 16, Item 9 (once gout is confirmed, take uric-acid–lowering drugs long term). About 7.4% of Han Chinese carry the HLA-B*5801 genotype versus 0.7% of White people. Carriers on allopurinol are more likely to get life-threatening severe drug rash; Asian risk of hypersensitivity syndrome is 3 times that of White people. This is a drug you can skip for now; there is no need to take that extra risk. Before starting, test for the genotype — Section 16, Item 9. The two kidney trials were in chronic kidney disease and type 1 diabetes; they cannot be stretched to “high uric acid is wholly harmless to kidneys.” They only reject “lowering uric acid with drugs protects the kidneys.”

My note